About Sound Biologics

Qilu Puget Sound Biotherapeutic Corp. (Sound Biologics) is a privately held biotech company specializing in discovery and development of novel biotherapeutics. The company’s MabPairTM technology is a powerful new platform enabling production of two distinct monoclonal antibodies from a single cell line. Products derived via the MabPair platform will offer compelling advantages compared to bispecific antibody products or conventional antibody combinations, including full flexibility in choice of different Fc backbones for antibody effector function, streamlined regulatory and clinical development paths, and single-entity pricing power. Sound Biologics is actively sourcing discovery and clinical collaborations while continuing to build a robust internal pipeline.